By leveraging 2D and brain organoid models this projects aims to test gene-therapy approaches and conduct a targeted drug screen for the currently untreatable hereditary spastic paraplegia subtype SPG56, a disease that is caused by mutations in the CYP2U1 gene.

Project members

Lead investigators

Professor Ernst Wolvetang

Senior Group Leader
Wolvetang Group
UQ-StemCARE Director

Dr Hannah Leeson

Postdoctoral Research Fellow
Wolvetang Group